Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron‐Dependent PI3K/AKT/mTOR Signaling Pathway
Cancer Science · 2025-05 · 116 (5) · 1352-1365
DOI: 10.1111/cas.70015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025-03. Verfasst von Yufei Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Receptors, Transferrin, Endometrial Neoplasms, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aberrant iron metabolism is frequently observed in cancers, including endometrial cancer (EC). However, the role of transferrin receptor (TFRC), a key regulator of iron metabolism, remains unclear in endometrial cancer. We found transferrin receptor expression was significantly upregulated in endometrial cancer tissues compared to adjacent nontumor tissues, and high transferrin receptor levels were associated with poor prognosis. Functional studies revealed that transferrin receptor knockdown impaired endometrial cancer cell proliferation in vitro and in vivo, while transferrin receptor overexpression enhanced endometrial cancer cell proliferation. Mechanistically, transferrin receptor activated the PI3K/AKT/mTOR signaling pathway, as its knockdown suppressed the pathway, and rapamycin, an mTOR inhibitor, reversed transferrin receptor‐induced pathway activation and proliferation. Modulation of the labile iron pool by ferric ammonium citrate (FAC) or deferoxamine (DFO) rescued transferrin receptor‐induced biological effects. Additionally, AURKA was identified as a regulator of transferrin receptor expression. These findings demonstrate the oncogenic role of transferrin receptor in endometrial cancer and suggest that targeting iron homeostasis and the PI3K/AKT/mTOR pathway may represent potential therapeutic strategies for endometrial cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, Qingdao University, Qingdao, China.
- Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, China.
- Center of Tumor Immunology and Cytotherapy, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
ORCID-Profile: Yufei Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, Y., Ning, Y., Chen, Y., Tian, T., Gao, X., Kong, Y., Lei, K., & Cui, Z. (2025). Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron‐Dependent PI3K/AKT/mTOR Signaling Pathway. Cancer Science, 116(5), 1352-1365. https://doi.org/10.1111/cas.70015
Vancouver
Yang Y, Ning Y, Chen Y, Tian T, Gao X, Kong Y, et al. Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron‐Dependent PI3K/AKT/mTOR Signaling Pathway. Cancer Science. 2025;116(5):1352-1365. doi:10.1111/cas.70015
BibTeX
@article{Yang2025,
author = {Yang, Yufei and Ning, Ying and Chen, Yu and Tian, Tian and Gao, Xinyan and Kong, Yan and Lei, Ke and Cui, Zhumei},
title = {Transferrin Receptor Promotes Endometrial Cancer Proliferation by Activating the Iron‐Dependent PI3K/AKT/mTOR Signaling Pathway},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {5},
pages = {1352--1365},
doi = {10.1111/cas.70015}
}
EUVIMED